This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Related articles in The Oncologist Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ray-Coquard, I. Articles by Blay, J.-Y. Search for Related Content PubMed PubMed Citation Articles by Ray-Coquard, I. Articles by Blay, J.-Y.

Sarcoma Research Series

A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens

¹Centre Léon Bérard and UJOMM H. E. Herriot, Lyon, France; ²I. Gustave Roussy, Villejuif, France; ³University College Hospital, London, United Kingdom; ⁴U.Z. Leuven, Leuven, Belgium; ⁵Institut Bergonie, Bordeaux, France; ⁶U.Z. and Erasmus, Rotterdam, The Netherlands; ⁷European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium; ⁸University Leiden, The Netherlands

Key Words. Sarcoma • Synovial sarcoma • HER-1 • Expression microarrays • Gefitinib

Correspondence: J.-Y. Blay, M.D., Ph.D., Unité Cytokine et Cancer, Unité INSERM U590, Centre Léon Bérard, 28, rue Laennec, 69008 Lyon, France. Telephone: +33478782757; Fax: +3347878782716; e-mail: blay{at}lyon.fnclcc.fr

Disclosure: This article references unlabeled use of gefitinib (AstraZeneca) for use in a phase II trial in HER-1 synovial sarcomas. J.-Y.B. has received consulting fees and has contracted research from Novartis, Pfizer, GlaxoSmithKline, and Roche; and has received unrestricted grant for research from Novartis. P.H. has received consulting fees from Novartis. No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Rationale. Advanced synovial sarcomas (SyS) refractory to doxorubicin and ifosfamide are highly resistant to the currently available cytotoxic agents. Based on a report showing a specific overexpression of HER-1 in SyS, we investigated an HER-1 inhibitor, gefitinib, in refractory SyS.

Subjects and Methods. To establish the efficacy and safety of gefitinib in HER-1 – positive SyS refractory to one or two lines of doxorubicin- and ifosfamide-based chemotherapy, a phase II study was conducted from December 2002 to October 2005 by 12 centers of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Gefitinib was given at a 500-mg/day oral dose until progression or intolerance.

Results. Forty-eight patients were included (46 eligible). All patients had previously received chemotherapy for metastatic disease, with a median number of two lines (range, 1–4). The most frequent metastatic sites were the lungs (n = 44, 92%), lymph nodes (n = 11, 23%), and soft tissues (n = 10, 21%). The median duration of treatment was 43 days (range, 13–315). Treatment was interrupted in five patients (10%). Treatment was halted for progression in 45 (94%) patients. The best response was stable disease in 10 patients (21%). Disease progression occurred in 32 patients (70%), with a median time to disease progression of 6 weeks. Progression-free survival at 4 and 6 months was 21% and 6%, respectively.

Conclusion. The results show that gefitinib monotherapy in advanced SyS refractory to conventional chemotherapy did not demonstrate sufficient activity to warrant further investigation in this setting. This may suggest that HER-1 is not a critical protein in tumor progression in this disease.

Related articles in The Oncologist:

Editorial: The Long and Winding Road to Better Cancer Cell–Specific Therapies

Stefan Sleijfer and Erik Wiemer
The Oncologist 2008 13: 593-595. [Full Text]  

This article has been cited by other articles:

				S. Sleijfer and E. Wiemer Editorial: The Long and Winding Road to Better Cancer Cell-Specific Therapies Oncologist, May 1, 2008; 13(5): 593 - 595. [Full Text] [PDF]